Stockreport

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer ...

Eterna Therapeutics Inc.  (ERNA) 
PDF iMSC-based cell therapy (ERNA-101) to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research agreement with The U [Read more]